A5036440015- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Medical Imaging and Pathology Studies
- Radiomics and Machine Learning in Medical Imaging
- Cancer therapeutics and mechanisms
- Cancer Genomics and Diagnostics
- Neuroendocrine Tumor Research Advances
- Medical Imaging Techniques and Applications
- Gastric Cancer Management and Outcomes
- Metastasis and carcinoma case studies
- RNA modifications and cancer
- Peptidase Inhibition and Analysis
- Salivary Gland Tumors Diagnosis and Treatment
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Ferroptosis and cancer prognosis
- Esophageal Cancer Research and Treatment
- Cancer Diagnosis and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer-related Molecular Pathways
- Inflammatory Biomarkers in Disease Prognosis
- Nerve injury and regeneration
Kanagawa Prefectural Hospital Organization
2016-2025
Kanagawa Cancer Center
2016-2025
Yokohama City University
1999-2021
Aso Iizuka Hospital
2021
Dharmais Cancer Hospital
2021
Hudson Institute
2021
Japanese Foundation For Cancer Research
2019
The Cancer Institute Hospital
2019
358 (Finland)
2011
Health Foundation
2007
PURPOSE The open-label, phase III POSEIDON study evaluated tremelimumab plus durvalumab and chemotherapy (T + D CT) (D versus alone (CT) in first-line metastatic non–small-cell lung cancer (mNSCLC). METHODS Patients (n = 1,013) with EGFR/ ALK wild-type mNSCLC were randomly assigned (1:1:1) to 75 mg 1,500 platinum-based for up four 21-day cycles, followed by once every 4 weeks until progression one additional dose; progression; or six cycles (with without maintenance pemetrexed; all arms)....
Background Immune checkpoint inhibitor (ICI) therapy has substantially improved the overall survival (OS) in patients with non-small-cell lung cancer (NSCLC); however, its response rate is still modest. In this study, we developed a machine learning-based platform, namely Cytokine-based ICI Response Index (CIRI), to predict of NSCLC based on peripheral blood cytokine profiles. Methods We enrolled 123 and 99 who received anti-PD-1/PD-L1 monotherapy or combined chemotherapy training validation...
ObjectivesTo describe the treatment patterns and determine effectiveness safety of nivolumab for non-small cell lung cancer (NSCLC) in real-world setting Japan.Materials methodsJapanese patients with NSCLC who received were analyzed retrospectively. Patients had started between April 2016 December enrolled. Information regarding patient demographics clinical backgrounds, from diagnosis to post-nivolumab treatment, that treatments just before after programmed death-ligand 1 (PD-L1) expression...
9506 Background: In NEJ026, a phase III trial comparing bevacizumab plus erlotinib (BE) to monotherapy (E) for EGFR-mutated non-small-cell lung cancer (NSCLC), we demonstrated the progression-free survival (PFS) of BE was significantly superior E (Saito et al. Lancet Oncol. 2019 May;20(5):625-635.). However overall analysis were immature at cutoff date. Methods: Chemotherapy-naïve pts with advanced non-squamous NSCLC harboring EGFR-mutation randomly assigned receive either combination (150...
The primary analysis (median follow-up 34.9 mo across all arms) of the phase 3 POSEIDON study revealed a statistically significant overall survival (OS) improvement with first-line tremelimumab plus durvalumab and chemotherapy (T+D+CT) versus CT in patients EGFR ALK wild-type metastatic NSCLC (mNSCLC). D+CT had trend for OS that did not reach statistical significance. This article reports prespecified analyses after long-term >5 y). A total 1013 were randomized (1:1:1) to T+D+CT, D+CT, or...
9006 Background: Development of treatment for EGFR-mutated non-small-cell lung cancer (NSCLC) had been focused on monotherapy gefitinib, erlotinib, or afatinib. Combinations EGFR-TKIs and VEGF inhibitors are one candidates next strategy tumor. We conducted a phase III study comparing BE to E. Methods: Chemotherapy-naïve pts with advanced non-squamous NSCLC harbouring EGFR-mutation were randomly assigned receive either combination erlotinib (150 mg daily) plus bevacizumab (15 mg/kg iv q3w)...
Abstract IMpower132 explored the safety and efficacy of atezolizumab plus pemetrexed platinum‐based chemotherapy as first‐line treatment for advanced non‐small‐cell lung cancer (NSCLC). Key eligibility criteria phase 3, open‐label, study included age ≥18 y, histologically or cytologically confirmed non‐squamous NSCLC per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, Eastern Cooperative Oncology Group performance status 0/1, no prior systemic stage IV NSCLC. Patients...
Importance The combination of an antibody to programmed cell death-1 (PD-1) or its ligand (PD-L1) with chemotherapy is the standard first-line treatment for metastatic non–small lung cancer (NSCLC). Bevacizumab expected enhance efficacy not only but also PD-1/PD-L1 antibodies through blockade vascular endothelial growth factor–mediated immunosuppression, further data are needed support this. Objective To evaluate and safety bevacizumab administered platinum therapy atezolizumab in patients...
As first-line treatment for stage IV or recurrent non-small cell lung cancer, combination immunotherapy with nivolumab and ipilimumab, without chemotherapy, had demonstrated survival benefits over chemotherapy; however, data on Japanese patients are limited.
IntroductionIn the phase 3 POSEIDON study, first-line tremelimumab plus durvalumab and platinum-based chemotherapy (T+D+CT) significantly improved overall survival (OS; hazard ratio [HR] 0.77 [95% confidence interval {CI} 0.65–0.92]; P=.0030) progression-free (PFS) versus alone (CT) in patients with metastatic NSCLC (mNSCLC), leading to approval for this regimen. We report outcomes by programmed cell death ligand-1 (PD-L1) tumor (TC) expression level.MethodsPatients EGFR/ALK wild-type mNSCLC...
Anti-vascular endothelial growth factor (VEGF) agents in combination with immunotherapies have improved outcomes for cancer patients, but predictive biomarkers not been elucidated. We report here a preplanned analysis the previously reported APPLE study, phase 3 trial evaluating efficacy of bevacizumab atezolizumab, plus platinum chemotherapy metastatic, nonsquamous non-small cell lung (NSCLC). investigated correlation serum VEGF-A and its isoforms at baseline treatment response by using an...
ABSTRACT Pulmonary carcinosarcoma is a rare tumor composed of non‐small‐cell carcinomas and sarcomatous elements, which poorly differentiated in most cases. We present case with well‐differentiated carcinomatous component that required differential diagnosis from tumors derived teratomas, such as teratocarcinosarcoma. 68‐year‐old man who visited our hospital for an examination 22‐mm lung tumor. The patient underwent left S1+2 segmentectomy, his postoperative course was uneventful. No...
BACKGROUND Bevacizumab combined with platinum‐based chemotherapy has been established as a standard treatment option in the first‐line setting for advanced nonsquamous non–small cell lung cancer (NSCLC). However, there no evidence to support use of bevacizumab beyond disease progression such patients. METHODS West Japan Oncology Group 5910L was designed multicenter, open‐label, randomized, phase 2 trial docetaxel versus plus every 3 weeks patients recurrent or metastatic NSCLC whose had...